PMID: 7538704Jan 1, 1995Paper

Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF

Tumori
S Cascinu, G Catalano

Abstract

Elderly patients constitute the largest group of advanced gastric cancer patients. Since there is a widespread misconception that the elderly are poorly tolerant of chemotherapy, most of them are untreated or receive a less aggressive but also less efficacious chemotherapy. However, because tolerance and response to cancer seem to vary more with physiologic age than chronologic age, we evaluated the feasibility and activity of an intensive weekly chemotherapy in elderly gastric cancer patients. 23 advanced gastric cancer patients (13 males and 10 females), older than 70 years, received weekly: cisplatin, 40 mg/m2 i.v.; epi-doxorubicin, 35 mg/m2 i.v.; 6S-leucovorin, 250 mg/m2 i.v.; 5-fluorouracil, 500 mg/m2 i.v.; and glutathione, 1.5 g/m2 G-CSF, at the dose of 5 micrograms/kg, was administered daily from the day after to the day before each chemotherapy administration. Toxicity was mild. The most common adverse effects were leukopenia (grade 3 in 2 patients); thrombocytopenia (grade 3 in 1 patient) and anemia (grade 3 in 3 patients). Five patients (20%) achieved a complete response and 9 (39%) a partial response, resulting in an overall response rate of 59% (95% CI, 40% to 78%). The median survival time was 13 months for all the...Continue Reading

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K KitamuraT Takahashi
Neurosurgery Clinics of North America
J P Elliott, P D Le Roux
© 2021 Meta ULC. All rights reserved